|
|
|
|
Office Locations:
|
8 Newbury Street, Suite 301
Boston, MA 02116
| |
|
|
|
|
|
Financial Services
Information Technology
Life Sciences & Healthcare
Software & Internet
Sports & Entertainment
|
|
|
Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives. With over $295 billion in assets under management as of December 31, 2024, Blue Owl invests across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Assets. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. The firm provides capital to the world's leading alternative investment firms, primarily focused on acquiring minority equity stakes in established private market managers. As part of Blue Owl's established relationship with the NBA, the firm is building a diversified portfolio of minority equity investments in professional basketball teams, aiming to become the buyer of choice for selling owners. The firm's Real Assets platform has established itself as a leader in investing across asset classes and geographies, offering flexible capital solutions to tenants, borrowers, and hyperscalers.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
| Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Craig W. Packer | |
| |
Co-President | |
| Doug Ostrover | |
| |
Co-Chief Executive Officer | |
| Marc Lipschultz | |
| |
Co-Chief Executive Officer | |
| Marc Zahr | |
| |
Co-President | |
| Michael Rees | |
| |
Co-President | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
04/06/2026
|
Ambrosia Biosciences
|
CO
|
$100,000,000
|
Series B
|
02/19/2026
|
Vestwell
|
NY
|
$385,000,000
|
Series E
|
01/06/2026
|
Interos
|
VA
|
$20,000,000
|
Venture
|
10/27/2025
|
Electra Therapeutics
|
CA
|
$183,000,000
|
Series C
|
10/02/2025
|
Star Therapeutics
|
CA
|
$125,000,000
|
Series D
|
06/16/2025
|
Juniper Square
|
CA
|
$130,000,000
|
Series D
|
|
|
|
|
|
|
|